Navigation Links
Divergence Raises $11.8 Million in Series C Financing
Date:2/11/2009

Biotechnology firm Divergence, Inc., a world leader in developing products for the control of parasites in agriculture and medicine, today announced that it has raised $11.8 million in a Series C financing round that will further its efforts to create solutions for one of the major causes of crop yield loss for farmers.

St. Louis, MO (PREWB) February 11, 2009 -- Biotechnology firm Divergence, Inc., a world leader in developing products for the control of parasites in agriculture and medicine, today announced that it has raised $11.8 million in a Series C financing round that will further its efforts to create solutions for one of the major causes of crop yield loss for farmers.

MidPoint Food and Ag Fund LP acted as lead investor in the round. Other institutional investors included Prolog Ventures LP and certain partners of William Blair & Co. The round included 41 returning investors including all members of Divergence's Board of Directors. The financing more than doubles the amount of equity capital raised by the company since its inception.

Proceeds from the financing will be used to advance Divergence's nematicide program. The company is developing molecules for the control of plant parasitic nematodes. Nematode control is the largest unsolved pest problem in agriculture limiting the yield of crops worldwide and causing billions of dollars in crop damage annually. Divergence has discovered the first novel mode of action for this market in more than 20 years. The new molecules feature human and environment safety profiles that are vastly superior to traditional nematicides. The funding will also support the Company's continued development of crops that are resistant to nematodes, as well as its innovative, broad-based research platforms Harvest™, STEM™ and RNA interference.

"This financing, especially given the sophistication of the participat
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
2. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)
3. JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism
4. Anacor Raises $50 Million in Equity Financing
5. MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile
6. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
7. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
8. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
9. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
10. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
11. MacroGenics Raises $25M in Series D-2 Financing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Divergence Raises $11.8 Million in Series C Financing
(Date:7/10/2014)... have shelled out for crude 3-D glasses, polarized ... experience. These basic devices, used to trick the ... soon be rendered obsolete with the introduction of ... researchers. , TAU doctoral students Yuval Yifat, Michal ... holography based on nanoantennas that could be used ...
(Date:1/15/2014)... , "The interface is the device," Nobel laureate ... properties to be found at the junctures where ... world of nanotechnology, the interfaces between layers of ... in such high-tech favorites as spintronics, high-temperature superconductors, ...
(Date:1/15/2014)... Vernon Hills, IL (PRWEB) January 15, 2014 ... Cole-Parmer to find hard-working items for the lab, from ... designated as Guaranteed-in-Stock (GIS)—ready to ship when you order. ... Masterflex® Peristaltic Pumps , from the L/S® model ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
Breaking Biology Technology:Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... SHANGHAI, Sep. 4 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: ... Chinese firm,specializing in the manufacture, research, development, marketing ... Company,s,management team will attend the Susquehanna International Group ... The SIG 3rd Annual ...
... , AURORA, Ontario, Sept. 4 Helix BioPharma ... has accepted subscriptions for the purchase, by way of private placement, ... gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private ... unit consists of one common share and one common share purchase ...
... Kendle (Nasdaq: KNDL ), a leading, global full-service ... the upcoming Robert Baird 2009 Health Care Conference on Sept. ... New York City. , , (Logo: ... Kendle,s formal presentation will be given by Senior Vice President ...
Cached Biology Technology:China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit 2Helix BioPharma Announces $13.5 Million Private Placement 2Kendle to Present at Robert Baird 2009 Health Care Conference 2
(Date:7/10/2014)... even improve the state of fisheries resources in ... Mediterranean has deteriorated over the past 20 years. ... reported in the Cell Press journal Current ... stringent monitoring of Mediterranean fishing activities, better enforcement ... Mediterranean waters. , Their data show that the ...
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) and ... Medicine today announced they will be partnering with ... drugs. , Under the agreement with Shanghai-based HD ... the costs and risks of discovery and development ... own any intellectual property and commercialization rights to ...
(Date:7/10/2014)... company housed at NJIT,s business incubator, received a $1.4 ... surgeons will use to staunch bleeding during brain surgery. ... site, and the natural bio-polymer solutions in the gel ... 30 seconds. , The gel can shorten an ... into less time for the patient,s skull to be ...
Breaking Biology News(10 mins):Mediterranean fish stocks show steady decline 2Marshall University to partner with international company in drug development venture 2A start-up at NJIT develops bleeding-control gel for brain surgery 2
... , This release is also available in Chinese ... it the anti-sunscreen. That,s more or less the description of ... light-catching substances that could be added to photovoltaic materials in ... electricity. Research reported in the journal ...
... 2010) Autism Speaks, Chief Science Officer Geraldine ... environmental risk factors for autism spectrum disorders as ... Works, Subcommittee on Children,s Health convened a special ... autism spectrum disorders (ASD) and related neurodevelopmental disorders. ...
... for two competitive grants to better understand and manage outbreaks ... fisheries in Puget Sound. The grants cover the first year ... the next three years. NEW FORECAST ... goal of one project is to develop a forecasting ability ...
Cached Biology News:Selenium makes more efficient solar cells 2Autism Speaks on US Senate hearing on potential environmental health factors in autism 2Autism Speaks on US Senate hearing on potential environmental health factors in autism 3New research to improve management of harmful algal blooms in Puget Sound 2
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
... The versatile Promega Flipper® Racks are ... of your small tubes. These polypropylene racks ... choice for freezer storage. They may also ... Each rack is two-sided; one side accommodates ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
...
Biology Products: